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Background: Published incidence rates of human salmonella infections are mostly based on numbers of stool
culture-confirmed cases reported to public health surveillance. These cases constitute only a small fraction of all
cases occurring in the community. The extent of underascertainment is influenced by health care seeking
behaviour and sensitivity of surveillance systems, so that reported incidence rates from different countries are not
comparable. We performed serological cross-sectional studies to compare infection risks in eight European
countries independent of underascertainment.
Methods: A total of 6,393 sera from adults in Denmark, Finland, France, Italy, Poland, Romania, Sweden, and The
Netherlands were analysed, mostly from existing serum banks collected in the years 2003 to 2008. Immunoglobulin
A (IgA), IgM, and IgG against salmonella lipopolysaccharides were measured by in-house mixed ELISA. We
converted antibody concentrations to estimates of infection incidence (‘sero-incidence’) using a Bayesian
backcalculation model, based on previously studied antibody decay profiles in persons with culture-confirmed
salmonella infections. We compared sero-incidence with incidence of cases reported through routine public health
surveillance and with published incidence estimates derived from infection risks in Swedish travellers to those
countries.
Results: Sero-incidence of salmonella infections ranged from 56 (95% credible interval 8–151) infections per 1,000
person-years in Finland to 547 (343–813) in Poland. Depending on country, sero-incidence was approximately 100
to 2,000 times higher than incidence of culture-confirmed cases reported through routine surveillance, with a trend
for an inverse correlation. Sero-incidence was significantly correlated with incidence estimated from infection risks
in Swedish travellers.
Conclusions: Sero-incidence estimation is a new method to estimate and compare the incidence of salmonella
infections in human populations independent of surveillance artefacts. Our results confirm that comparison of
reported incidence between countries can be grossly misleading, even within the European Union. Because
sero-incidence includes asymptomatic infections, it is not a direct measure of burden of illness. But, pending further
validation of this novel method, it may be a promising and cost-effective way to assess infection risks and to
evaluate the effectiveness of salmonella control programmes across countries or over time.
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Together with Campylobacter spp., the non-typhoid
serovars of Salmonella enterica subspecies enterica
(hereafter referred to as “salmonella”) are the most
commonly diagnosed bacterial cause of foodborne
infections in Europe [1] and other industrialized coun-
tries, e.g. the USA [2], Canada [3], Australia [4]. Symp-
toms range from mild, self-limiting diarrhoea to
systemic infection with fatal outcome. Acute salmonella
infection may be complicated by serious sequelae, such
as reactive arthritis [5]. In the USA, non-typhoid sal-
monella are estimated to be the leading cause of
hospitalization and deaths attributable to consumption
of contaminated food, causing 35% of such hospitaliza-
tions and 28% of such deaths [6].
Published data on the incidence of salmonella infec-
tions are generally based on notifications of stool
culture-confirmed cases [1,2]. These cases constitute
only a small fraction of all cases occurring in the com-
munity. A sequence of events must occur so that a sick
person in the community gets registered as a case in a
surveillance system: the person must consult a health
care provider, he/she must be asked to submit a stool
sample, he/she must comply with this, the stool sample
must be sent to and arrive at a laboratory in satisfactory
condition, it must be tested for salmonella, the test
must be positive, and the positive test result must be
reported. All these factors may differ considerably
among countries or states, due to differences in
patients’ health seeking behaviour and accessibility of
health services, in clinical practices regarding stool
examination, in diagnostic practices and test sensitivity
in clinical laboratories. These factors are influenced by
cultural, infrastructural and economic aspects and de-
termine the degree of “underdiagnosis”. Finally, a diag-
nosed case will go unnoticed by the surveillance system
if not reported (“underreporting”). We use the term
“underascertainment” for the joint effect of underdiag-
nosis and underreporting. Because of the varying extent
of underascertainment direct comparison of reported
incidence rates from different countries or states is po-
tentially misleading.
Little is known about the true community incidence of
salmonella infections in Europe. Several studies have
aimed to estimate so-called multipliers, i.e. the number
of cases occurring in the community per one reported
case. Community surveys of acute gastrointestinal infec-
tion (AGI) prevalence by telephone interviews were
done in several countries, e.g. Norway [7], Ireland [8],
Malta [9], Denmark [10], France [11], and Poland [12].
However, due to their retrospective design these studies
mostly lack aetiological diagnoses and are prone to recall
bias. Prospective community cohort studies of AGI in-
cluding microbiological diagnostics were undertaken inEngland in 1993–1996 [13], in the Netherlands in 1998–
1999 [14,15], and in the United Kingdom (UK) in 2008–
2009 [16]. The estimated community incidence of
salmonella-associated AGI was similar in the Nether-
lands and England (3.3 and 2.2 per 1,000 person-years,
respectively) in the 1990s, but the degree of underascer-
tainment was markedly higher in the Netherlands than
in England (multipliers of 14.3 and 3.2, respectively).
The recent UK study revealed a lower population inci-
dence (0.6 per 1,000 person-years), but the higher multi-
plier of 4.7 indicates increasing underascertainment
compared to the situation in England in 1993–1996.
Due to their very high cost and demanding logistics such
cohort studies cannot be easily replicated.
In the USA, community incidence of salmonella-
associated AGI was estimated by combining surveillance
data with information on health seeking behaviour and
diagnostic practices from laboratory and population sur-
veys in FoodNet areas [17], yielding an incidence estimate
of 5.2 per 1,000 (multiplier ~39) for the period 1996–1999
[18]. For the period 2000–2008, the incidence estimate
was 3.4 per 1,000 (90% credible interval [CI] 2.2-5.6) and
the multiplier 29 (90% CI 18–48) [6]. Similar such “multi-
plier studies” in Canada and Australia showed similar
results. For Canada, the estimated incidence was 2.5-6.9
per 1,000 (multiplier 13–37) in 2000–2001 [3]. For Aus-
tralia, it was 2.6 (95% CI 1.5-6.2) per 1,000 (multiplier 7
[95% CI 4–16]) in 2005 [4]. However, as discussed in [4],
such estimates are mostly based on extrapolations from
limited data and/or expert assumptions about the various
steps leading to underascertainment, resulting in large un-
certainties of the estimates.
As a basis for decision making in public health and for
the assessment of the health and economic burden of
salmonellosis, more reliable estimates of the true com-
munity incidence of salmonella infections (and other
foodborne pathogens) are highly desirable. We therefore
strived to develop an alternative method of estimating
the community incidence of salmonella infections, which
should be affordable and independent of ascertainment
artefacts, expert opinion and accuracy of interviewees’
recall. To that end, we estimated the community inci-
dence of salmonella infections from measurements of
salmonella-specific antibodies in cross-sectional sero-
surveys of the general population.
We present here the results of a pilot study in eight
European Union member states. We compare our so-
called ”sero-incidence” estimates [19] with the incidence
of salmonella cases reported through the countries’ re-
spective surveillance systems and with published inci-
dence estimates derived from infection risk in returning
Swedish travellers [20], representing an alternative sur-
veillance approach insensitive to differences in case as-
certainment among countries.
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Study population
Existing serum banks were identified in Denmark, Fin-
land, France, Italy, Poland, Sweden, and the Nether-
lands. At least 500 serum samples were selected from
these serum banks with criteria: adults (target group
18–60 years of age), sampling dates ideally covering
≥12 consecutive months, geographically representative
of the sampled population. Sera had been collected
over a period of 5 years (January 2003 to January
2008) with the exception of the Finnish sera, which
were drawn September 2000 through March 2001. A
total of 6,393 serum samples were included in the
study (Table 1).
Serum samples from Finland, Sweden, and the Neth-
erlands were subsamples of serum banks that had been
collected from the resident national population for
other studies, by using probability sampling schemes
to achieve best possible representativeness [21,22]. The
French serum samples were from persons attending
routine free health checks proposed to all adults in the
general social insurance scheme, which covers >80%
of the population [23]. The Danish serum samples had
been collected from the resident population in parts of
the capital city Copenhagen and its sub-urban and
rural surroundings. In Poland and Italy, serum banks
of residual sera from persons consulting the health ser-
vices for a variety of reasons were used. Indications for
blood draw for the Polish sera were diagnostic screen-
ing before surgical procedures (~75% of sera), health
checks required for employment (~15%), miscellaneous
(~10%) [24]. Italian sera originated from a previous
study, where patients with acute infections or im-
munosuppression were excluded as per study protocol
[25].
In Romania no suitable serum bank was found. There-
fore serum samples were prospectively collected in one
district from each of the country’s eight provinces from
people attending the district medical services for reasons
unrelated to AGI during September 2007.Table 1 Serum collections tested for antibodies against salmo
Country Period of serum collection Number
Finland Sept. 2000 - March 2001 500
Sweden a May 2007 - Jan. 2008 525
Denmark June 2006 - July 2007 178
The Netherlands Jan. 2006 - June 2007 105
Italy Jan. 2003 - April 2004 516
Romania Sept. 2007 509
France May 2003 - April 2004 101
Poland 2004 b 500
a In Sweden sera from older people were included in order to achieve a sufficient s
b Sera from Poland were randomly chosen from a collection of sera from 2004 thatAntibody measurement
Serum samples were analysed for antibodies against sal-
monella lipopolysaccharide (LPS) antigens with an in-
house ELISA using commercially available LPS antigens
(SIGMA, Copenhagen) of the two most common human
serovars in Europe, namely S. Enteritidis (O-antigens
1,9,12) and S. Typhimurium (O-antigens 4,5,12) as cap-
ture antigen in the solid phase. Initial attempts to de-
velop serovar-specific ELISAs showed that there was
extensive cross-reactivity between the two serovars.
Therefore we developed a mixed ELISA with a 1:1 mix-
ture of both antigens [26]. The mixed ELISA was vali-
dated by testing 964 serum samples from patients with
stool culture-confirmed infections with S. Enteritidis or
S. Typhimurium, and 300 healthy blood donors as refer-
ence group.
In each serum sample, immunoglobulin A (IgA), IgG
and IgM was measured separately, as described in [26].
Ig concentrations were expressed in arbitrary units of
optical density (OD). All serum samples were analyzed
at the Department of Microbiological Surveillance and
Research at Statens Serum Institut, Copenhagen, to ex-
clude inter-laboratory variability.
Surveillance data and data from other studies
Numbers and incidence rates of reported culture-
confirmed cases of salmonella, corresponding to the
period of serum collection, were directly extracted from
national surveillance databases by the authors. Because
of the short period of serum collection in Romania, we
calculated an annualized incidence rate from case
reports in the two preceding months in order to com-
pensate for seasonal incidence fluctuations. In France
and the Netherlands, there is no mandatory notification
of salmonella infections. Reported incidence rates were
adjusted for estimated population coverage of the re-
spective salmonella sentinel surveillance systems of 50%
(France) and 64% (the Netherlands).
We also compared our sero-incidence estimates with
estimates of salmonella infection incidences from a studynella
of sera Female-to-male ratio Age [mean (range)]
1.1 44 (30–59)
1.7 51 (18–76)
0 1.2 49 (18–71)
3 1.6 39 (18–60)
1.0 34 (18–60)
1.0 38 (18–60)
0 1.0 38 (18–60)
1.6 37 (18–60)
ample size.
had no exact sampling dates recorded.
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travel to the respective country [20].
Statistical analysis
For each country, we calculated median OD values by Ig
isotype and estimated the incidence of salmonella infec-
tions based on the serological results. This was done
with a Bayesian backcalculation model, which we have
described in detail previously [19]. In brief, the model is
based on the kinetics of IgG, IgM, and IgA observed
during a 18-month follow-up study with repeated bleed-
ing of 302 adult Danish patients with stool culture-
confirmed salmonella infections. Ig concentration is
modelled as a function of time since infection, taking
into account observed inter-individual variations of the
antibody response.
In a “reverse” application, the model generates a prob-
ability distribution of the likely time-since-last-infection
for a given set of IgA, IgG and IgM values measured in
any single serum sample. The individual estimates of
time-since-infection for each serum sample in the cross-
sectional surveys were converted to an estimate of the
annual infection incidence (“sero-incidence”) in the
sampled population; point estimates and 95% credible
intervals are reported. The sample size of ≥500 sera from
each country resulted from simulation runs of the back-
calculation model, which showed that precision of the
estimates decreased rapidly with smaller sample sizes.
By dividing the sero-incidence estimates by the inci-
dence of reported cases, we calculated multipliers, which
indicate how many infections have likely occurred in the
population per case reported through routine public
health surveillance.Table 2 Salmonella sero-incidence, serum immunoglobulin co
incidence estimate derived from infection risk in Swedish tra
Country Sero-incidence a
(95 % CI)
IgG b IgM b IgA b
(A)
Finland 56 (8–151) 0.05 0.09 0.03
Sweden 58 (8–155) 0.06 0.10 0.02
Denmark 84 (41–141) 0.07 0.10 0.04
The
Netherlands
149 (78–245) 0.17 0.11 0.04
Italy 239 (115–411) 0.24 0.14 0.06
Romania 385 (217–613) 0.32 0.19 0.07
France 404 (272–573) 0.25 0.21 0.07
Poland 547 (343–813) 0.36 0.20 0.09
a per 1000 person-years.
b median serum immunoglobulin concentration in arbitrary units of optical density.
c adjusted for proportion of domestically acquired infections (~20%).
CI = credible interval.
n/a = not applicable.Spearman rank test was used to examine the correl-
ation between sero-incidence and reported incidence,
as well as between sero-incidence and incidence esti-
mates derived from infection rates in Swedish travellers.
P-values <0.05 were considered statistically significant.
Ethical considerations
The existing serum banks in Denmark, Finland, France,
Poland, Sweden, and The Netherlands had been estab-
lished for research purposes with corresponding ethics
committee approvals. The sera from Italy and Romania
were left-over sera from blood samples taken for diag-
nostic purposes. Patients had consented to the use for
research purposes; a formal ethics committee approval
was deemed unnecessary by the responsible public
health institutes. All serum samples were anonymised.
Results
Sero-incidence estimates
The main outcome of our study is the country-specific
sero-incidence estimates (Table 2, Figure 1). Finland and
Sweden had the lowest sero-incidences of 56 (95% CI 8–
151) and 58 (95% CI 8–155) infections per 1,000 person-
years, respectively. This is equivalent to one infection
per person approximately every 17 years, whereas the
highest sero-incidence of 547 (95% CI 343–813) infec-
tions per 1,000 person-years in Poland corresponds to
approximately one infection per person every second
year. The relative order of countries by median Ig con-
centration (regardless of Ig isotype) tended to be the
same as for sero-incidence. In countries with low sero-
incidence and low Ig values (Finland, Sweden, Den-
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Figure 1 Salmonella sero-incidence estimates in eight
European countries. Incidence of salmonella infections modeled
on the basis of antibody concentrations against Salmonella-LPS,
measured by in-house mixed ELISA in 6,393 serum samples
collected between 2000 and 2008.
Box: 25th and 75th percentile. Whiskers: 2.5th and 97.5th
percentile. DK = Denmark, FI = Finland, FR = France, IT = Italy,





























Figure 2 Salmonella sero-incidence and incidence of reported
cases. Spearman’s rho =−0.5, p = 0.2. Vertical bars: 95% credible
intervals py = person-years. DK =Denmark, FI = Finland, FR = France,
IT = Italy, NL = The Netherlands, PL = Poland, RO= Romania,
SE = Sweden.
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Netherlands, Italy, Romania, France, Poland), ODs for
IgG were higher than ODs for IgM.Comparison with other incidence data
Sero-incidence and incidence of reported cases showed a
trend towards an inverse correlation (Spearman’s rho =
−0.5, p = 0.2; Figure 2). Among the three countries with
the highest incidences of reported cases were those with
the lowest (Finland, Sweden) as well as with the highest
(Poland) sero-incidence. The multipliers between sero-
incidence and incidence of reported cases ranged from
102 for Finland to 9,625 for Romania. Considering Ro-
mania an outlier due to its exceptionally low reported
incidence, the multipliers varied by a factor of ~20
(range 102–2,010) and tended to increase with increas-
ing sero-incidence.Incidence estimates derived from infection risks in
Swedish travellers returning from the respective coun-
tries showed a statistically significant positive correlation
with sero-incidence (Spearman’s rho = 0.9, p = 0.007).
(Table 2, Figure 3). For Finland, the crude ratio of sero-
incidence and estimate from Swedish traveller infection
risk was 700. However, only ~20% of reported salmon-
ella infections in Finland are domestically acquired [27].
Because only the domestic infection risk determines the
incidence in Swedish travellers to Finland, an adjusted
multiplier of 140 (20% of 700) was included in Table 2.
With that adjustment, sero-incidences exceeded the inci-
dences estimated from infection risk in Swedish travel-
lers to the respective countries by a factor of 26 to 227.
Discussion
We estimated the incidence of human salmonella infec-
tions in eight European Union member states, using a
novel method based on cross-sectional sero-surveys and a
Bayesian backcalculation model [19]. These so-called
sero-incidences differed widely among participating coun-
tries from 56 to 547 infections per 1,000 person-years.
Sero-incidence estimates exceeded incidences of culture-
confirmed cases reported through routine surveillance by
a factor of ~100 to ~2,000, depending on country.
Sero-incidence was not correlated with incidence of
reported cases. If anything, there was a trend towards an
inverse correlation, albeit not statistically significant.
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Figure 3 Salmonella sero-incidence and population incidence
estimates derived from infection risks in Swedish travellers.
Spearman’s rho = 0.9, p = 0.007 py = person-years. DK = Denmark,
FI = Finland, FR = France, IT = Italy, NL = The Netherlands,
PL = Poland, RO= Romania. Population incidence estimates
derived from infection risks in Swedish travellers as reported in
[20].
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dences of culture-confirmed cases through their regular
surveillance systems than the other six countries.
These findings are compatible with the active salmon-
ella control programmes in both countries [28,29],
resulting in low infection rates in humans (as sup-
ported by serological results) and high proportion of
case ascertainment. Nevertheless, sero-incidence was
still ~100-130-fold higher than reported incidence.
Limitations
The mixed ELISA used to measure serum antibody con-
centrations is based on LPS antigens from S. Enteritidis
(serogroup D1) and S. Typhimurium (serogroup B).
These two serovars comprised 75-90% of reported sal-
monella cases in the European Union in 2004–2007
[30–32]. It is reasonable to assume that serum from
people infected with other salmonella serovars with
shared LPS antigens (i.e. belonging to serogroups B or
D) will be reactive in our ELISA, but we have no infor-
mation about possible cross-reactivity with antibodies to
salmonella from other serogroups. When calculating the
multiplier between sero-incidence and incidence of
reported cases, we used the number of all reported
cases, irrespective of serovar. Therefore the multipliers
may be underestimations.The serum samples were from adults only, whereas
the incidence of reported cases included all age groups.
Because reported incidence is generally higher in young
children, this was another factor contributing to under-
estimation of the multipliers.
The source of serum samples differed among countries.
In Finland, Sweden, and the Netherlands, the sampling
frame was the entire national resident population. In Den-
mark it was the resident population in one region,
whereas in France, Poland, Romania, and Italy serum sam-
ples had been collected from persons consulting the
health services for health checks or for illnesses unrelated
to acute gastroenteritis. These four countries also have the
highest sero-incidence estimates. It can be speculated that
the estimates may be biased, because people who are will-
ing to use and have good access to formal health services
were more likely to be sampled. However, this would only
bias the sero-incidence estimates upwards if the risk of
salmonella infection (diagnosed or not) in this group was
higher than in the general population. For people attend-
ing for health checks this seems unlikely, unless persons
with undeclared AGI or immunocompromising condi-
tions were included in the study in relevant numbers. The
validity of the high sero-incidence estimates is supported
by the fact that also infection risk in Swedish travellers is
highest in the same four countries. Future studies should
investigate what kind of sera could replace truly
population-representative serum collections, which are
non-existant or not accessible in many countries.
The larger sample size in some countries, including
older people in Denmark, allowed us to analyse the ef-
fect of age, gender, and sampling month on the sero-
incidence estimates in a multivariate regression model.
None of these three factors significantly influenced sero-
incidence estimates [33]. Therefore, we did not exclude
sera from older people or from countries with serum
collection during less than a whole year.
Finally, the backcalculation model is based on data of
antibody decay over time that was observed in salmonel-
losis patients in Denmark, a country with a relatively
low incidence of salmonella infections. It is difficult to
predict how this may have affected the sero-incidence
estimates for high incidence countries. If the antibody
response is stronger with frequent infections, our model
would overestimate infection incidence. However, if fre-
quent infections induce a weaker immune response, es-
pecially lower IgM production, our model would
underestimate infection incidence.
Comparison with other data
It was reassuring that, despite these limitations, the
sero-incidence estimates were correlated with the inci-
dence estimates derived from infection risk in returning
Swedish travellers. It should be noted that the infection
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tic salmonella transmission in the visited country,
whereas sero-incidence includes both domestic and
imported infections. This is particularly relevant in
countries with low incidence of domestic infections and
thus a relatively large proportion of imported infections.
How do our findings compare with data from other
studies attempting to estimate the population incidence of
salmonella-associated AGI? Based on data from the Dutch
prospective SENSOR community cohort study [14], and
adjusted for the trend in reported cases, Kemmeren et al.
[34] calculated a population incidence of 2.2 per 1,000 per-
sons in the Netherlands in 2004. In contrast, our sero-
incidence estimate for the Netherlands is 149 salmonella
infections per 1,000 person-years, about 70 times higher.
This discrepancy can at least partially be explained by
the fact that the SENSOR study counted episodes of
clinical gastroenteritis whereas sero-incidence includes
all infections inducing a sero-response, including those
with mild or possibly no symptoms (“subclinical infec-
tions”). Therefore the multiplier between reported inci-
dence and sero-incidence is a compound indicator of the
underascertainment of symptomatic cases through sur-
veillance and the ratio of illness episodes to subclinical
infections (“disease-to-infection ratio”) in the population.
We cannot directly estimate this ratio because we do
not have information on disease history from the serum
donors in our study. It is likely that the proportion of
subclinical infections increases with increasing sero-
incidence, reflecting partial immunity in the population
when contact with salmonella is frequent. In addition,
countries with high salmonella incidence may also have
less rigorous case ascertainment. A combination of both
effects likely explains our observation that the multi-
plier between sero-incidence and reported incidence
increased with increasing sero-incidence (Table 2).
To our knowledge salmonella-specific multiplier studies,
as performed in the USA, Canada and Australia [3,4,6,18],
have not been done in Europe. The mentioned studies
yielded estimates of the population incidence of
salmonella-associated AGI in the range of approximately
2 to 6 per 1,000 person-years. The ratios of the upper and
lower limits of the 95% credible intervals, if reported, were
approximately 2.5 to 4. This degree of uncertainty is very
similar to the uncertainty of our sero-incidence estimates,
with the exception of Finland and Sweden, where the
sero-incidence was so low that the sample size of only 500
sera resulted in very large credible intervals.
Perspectives
To further validate our method and inform interpret-
ation of the sero-incidence estimates, several additional
studies should be done. It should be determined what
proportion of all salmonella infections is sub-clinical,how that depends on the overall infection incidence, and
how antibody response after subclinical infection differs
from antibody response after illness. Longitudinal sero-
logical follow-up of salmonellosis patients should be
repeated in a high incidence country to investigate how
the antibody response is affected by frequent exposure
to salmonella. Antibody decay should also be studied in
children, because their immune response likely differs
from that in adults. This would be a prerequisite for
sero-incidence estimation from cross-sectional sero-
surveys in children. Sera from patients infected with
other salmonella serovars should be tested with our
ELISA to check if they cross-react.
To facilitate replication of sero-incidence studies in
other settings, it should be studied if truly population-
representative serum collections can be substituted by
more readily accessible serum samples, for instance from
blood donors, orthopaedic patients, or from screening
programmes in pregnancy. Even though such sera may
not be representative for the entire population, they
would be suitable for comparing incidences of salmon-
ella infections among countries, because a possible bias
should be similar in all countries.
Conclusions
Sero-incidence estimation is a promising new method to
estimate and compare the incidence of salmonella infec-
tions in human populations independent of the extent of
underascertainment of cases through routine public
health surveillance. Sero-incidence is not a direct meas-
ure of burden of illness, but it allows comparison of in-
fection risks among countries - information that is
valuable to assess for example the public health impact
of different food safety policies. Sero-incidence can also
be useful to monitor time trends of salmonella incidence
and evaluate the effect of control interventions, inde-
pendent of modifications of surveillance practice over
time. The method can potentially be applied to other
common infections, e.g. campylobacteriosis. While
reported incidences can serve to monitor trend over
time within a country, our results confirm that compari-
son of reported incidences among countries, even within
the European Union, can be grossly misleading.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GF coordinated implementation of the study, contributed to data collection,
analysis and interpretation, and wrote the manuscript. JS and PFMT
performed the statistical analyses. THC and KAK performed the serologic
tests and provided sera from Denmark. WvP, HdV, MST, LZ, MK, CJ, MCR,
YTHPvD provided sera and surveillance data from their respective countries.
In addition, all authors were involved in the study design, data interpretation
and reviewing several versions of the manuscript. All authors had full access
to all study data. GF and JS had final responsibility for the decision to submit
for publication. All authors read and approved the final manuscript.
Falkenhorst et al. BMC Public Health 2012, 12:523 Page 8 of 9
http://www.biomedcentral.com/1471-2458/12/523Acknowledgements
We are grateful to the curators of serum banks for giving us access to the
sera. We thank Dinna Krüger, Statens Serum Institut, for her assistance with
the serologic tests, and Sabrina Bacci, Statens Serum Institut, for logistic
support in connection with the Italian serum samples.
This project has been co-funded by Med-Vet-Net, a “Network of Excellence”
for research on the prevention and control of zoonoses, funded by the
European Commission within the 6th Framework Programme (contract no.
506122), and by the European Centre for Disease Control and Prevention,
project OJ/2009/06/03-PROC/2009/021. The contribution of PT has been
funded by POLYMOD, EU-FP6 contract SSP22-CT-2004-502084.
Med-Vet-Net as the principal funding source of this study accepted the
study design as proposed by the authors without modifications. The funders
had no involvement in the collection, analysis or interpretation of the data
or the writing of the manuscript.
Author details
1Division of Epidemiology, Statens Serum Institut, Copenhagen, Denmark.
2Department of Microbiological Diagnostics, Statens Serum Institut,
Copenhagen, Denmark. 3Centre for Infectious Disease Control, National
Institute for Public Health and the Environment (RIVM), Bilthoven, The
Netherlands. 4Infectious Diseases Department, Institut de Veille Sanitaire,
Saint Maurice, France. 5Department of Epidemiology, National Institute of
Public Health – National Institute of Hygiene, Warsaw, Poland. 6National
Center for Surveillance and Control of Communicable Diseases, National
Institute of Public Health, Bucharest, Romania. 7National Institute for Health
and Welfare, Helsinki, Finland. 8Department of Preparedness, Swedish
Institute for Communicable Disease Control (SMI), Solna, Sweden. 9Centro
Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto
Superiore di Sanità, Roma, Italy. 10Hubert Department of Global Health,
Rollins School of Public Health, Emory University, Atlanta, GA, USA.
11Department of Microbiological Surveillance and Research, Statens Serum
Institut, Copenhagen, Denmark.
Received: 3 February 2012 Accepted: 2 July 2012
Published: 16 July 2012
References
1. European Food Safety Authority, European Centre for Disease Prevention
and Control: The European Union Summary Report on Trends and
Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in
2010. EFSA J 2012, 10(2597):22–27. http://www.efsa.europa.eu/en/
efsajournal/doc/2597.pdf.
2. Centers for Disease Control and Prevention: Preliminary FoodNet data on
the incidence of infection with pathogens transmitted commonly
through food – 10 states, 2009. MMWR Morb Mortal Wkly Rep 2010,
59:418–422.
3. Thomas MK, Majowicz SE, Sockett PN, Fazil A, Pollari F, Doré K, Flint JA, Edge
VL: Estimated numbers of community cases of illness due to Salmonella,
Campylobacter and verotoxigenic Escherichia coli: Pathogen-specific
community rates. Can J Infect Dis Med Microbiol 2006, 17:229–234.
4. Hall G, Yohannes K, Raupach J, Becker N, Kirk M: Estimating community
incidence of Salmonella, Campylobacter, and Shiga toxin-producing
Escherichia coli infections, Australia. Emerg Infect Dis 2008, 14:1601–1609.
5. Mølbak K, Olsen JE, Wegener HC: Salmonella infections. In Foodborne
infections and intoxications. 3rd edition. Edited by Riemann HP, Cliver
DO. Amsterdam Boston Heidelberg. Academic Press Elsevier 2006, 57–136.
6. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones
JL, Griffin PM: Foodborne illness acquired in the United States–major
pathogens. Emerg Infect Dis 2011, 17:7–15.
7. Kuusi M, Aavitsland P, Gondrosen B, Kapperud G: Incidence of
gastroenteritis in Norway – a population-based survey. Epidemiol Infect
2003, 131:591–597.
8. Scallan E, Fitzgerald M, Collins C, Crowley D, Daly L, Devine M, Igoe D,
Quigley T, Robinson T, Smyth B: Acute gastroenteritis in Northern Ireland
and the Republic of Ireland: a telephone survey. Commun Dis Public
Health 2004, 7:61–67.
9. Gauci C, Gilles H, O'brien S, Mamo J, Stabile I, Ruggeri FM, Gatt A, Calleja
N, Spiteri G: The magnitude and distribution of infectious intestinal
disease in Malta: a population-based study. Epidemiol Infect 2007,
135:1282–1289.10. Müller L, Korsgaard H, Ethelberg S: Burden of acute gastrointestinal illness
in Denmark 2009: a population-based telephone survey. Epidemiol Infect
2012, 140:290–298.
11. van Cauteren D, de Valk H, Vaux S, Le Strat Y, Vaillant V: Burden of acute
gastroenteritis and healthcare-seeking behaviour in France: a
population-based study. Epidemiol Infect 2012, 140:697–705.
12. Baumann-Popczyk A, Sadkowska-Todys M, Rogalska J, Stefanoff P: Incidence
of self-reported acute gastrointestinal infections in the community in
Poland: a population-based study. Epidemiol Infect 2012, 140:1173–1184.
13. Wheeler JG, Sethi D, Cowden JM, Wall PG, Rodrigues LC, Tompkins DS,
Hudson MJ, Roderick PJ: Study of infectious intestinal disease in England:
rates in the community, presenting to general practice, and reported to
national surveillance. BMJ 1999, 318:1046–1050.
14. de Wit MA, Koopmans MP, Kortbeek LM, Wannet WJ, Vinjé J, van Leusden F,
Bartelds AI, van Duynhoven YT: Sensor, a population-based cohort study
on gastroenteritis in The Netherlands: incidence and etiology. Am J
Epidemiol 2001, 154:666–674.
15. van Pelt W, de Wit MA, Wannet WJ, Ligtvoet EJ, Widdowsen MA, van
Duynhoven YT: Laboratory surveillance of bacterial gastroenteric pathogens
in the Netherlands, 1991–2001. Epidemiol Infect 2003, 130:431–441.
16. Tam CC, Rodrigues LC, Viviani L, Dodds JP, Evans MR, Hunter PR, Gray JJ,
Letley LH, Rait G, Tompkins DS, O'Brien SJ: IID2 Study Executive
Committee: Longitudinal study of infectious intestinal disease in the UK
(IID2 study): incidence in the community and presenting to general
practice. Gut 2012, 61:69–77.
17. Scallan E: Activities, achievements, and lessons learned during the first
10 years of the Foodborne Diseases Active Surveillance Network:
1996–2005. Clin Infect Dis 2007, 44:718–25.
18. Voetsch AC, van Gilder TJ, Angulo FJ, Farley MM, Shallow S, Marcus R,
Cieslak PR, Deneen VC, Tauxe RV: Emerging Infections Program FoodNet
Working Group: FoodNet estimate of the burden of illness caused by
nontyphoidal salmonella infections in the United States. Clin Infect Dis
2004, 38(Suppl 3):127–134.
19. Simonsen J, Mølbak K, Falkenhorst G, Krogfelt KA, Linneberg A, Teunis PF:
Estimation of incidences of infectious diseases based on antibody
measurements. Stat Med 2009, 28:1882–1895.
20. de Jong B, Ekdahl K: The comparative burden of salmonellosis in the
European Union member states, associated and candidate countries.
BMC Publ Health 2006, 6:4.
21. National Public Health Institute (KTL): Methodology report Health 2000
survey. In Publications of the National Public Health Institute. Helsinki: KTL
2008, B26:13–17.
22. van der Klis FR, Mollema L, Berbers GA, de Melker HE, Cautinho RA: Second
national serum bank for population-based seroprevalence studies in the
Netherlands. Neth J Med 2009, 67:301–308.
23. Meffre C, Le Strat Y, Delarocque-Astagneau E, Antona D, Desenclos JC:
Prévalence des hépatites B et C en France en 200. Saint-Maurice: Institut
de Veille Sanitaire 2007, http://www.invs.sante.fr/surveillance/hepatite_c/
default.htm.
24. Smith JS, Rosinska M, Trzcinska A, Pimenta JM, Litwinska B, Siennicka J: Type
specific seroprevalence of HSV-1 and HSV-2 in four geographical regions
of Poland. Sex Transm Infect 2006, 82:159–163.
25. Rota MC, Bella A, Gabutti G, Giambi C, Filia A, Guido M, De Donno A,
Crovari P, Ciofi Degli Atti ML: Serological Study Group: Rubella
seroprofile of the Italian population: an 8-year comparison. Epidemiol
Infect 2007, 135:555–562.
26. Strid MA, Dalby T, Mølbak K, Krogfelt KA: Kinetics of the human
antibody response against Salmonella enterica serovars Enteritidis and
Typhimurium determined by LPS ELISA. Clin Vacc Immunol 2007,
14:741–747.
27. National Public Health Institute (KTL): Infectious Diseases in Finland 1995–
2004. In Publications of the National Public Health Institute. Helsinki: KTL
B 2005, 13:17–20 [http://www.ktl.fi/attachments/suomi/julkaisut/
julkaisusarja_b/2005/2005b13.pdf].
28. Sternberg-Lewerin S, Wahlström H, Häggblom P, Szanto E, Gustafsson P,
Forshell LP: The Swedish national salmonella control programme: Future
challenges. In Proceedings of the International Symposium on
Salmonella and Salmonellosis. St Malo, France 2006, I3S:531–534.
29. Kangas S, Lyytikäinen T, Peltola J, Ranta J, Maijala R: Costs of two
alternative salmonella control policies in Finnish broiler production.
Acta Vet Scand 2007, 49:35.
Falkenhorst et al. BMC Public Health 2012, 12:523 Page 9 of 9
http://www.biomedcentral.com/1471-2458/12/52330. European Food Safety Authority (EFSA): The community summary report
on trends and sources of zoonoses, zoonotic agents and antimicrobial
resistance in the European Union in 2004. EFSA J 2005, 310:23–27.
31. European Food Safety Authority (EFSA): The community summary report
on trends and sources of zoonoses, zoonotic agents, antimicrobial
resistance and foodborne outbreaks in the European Union in 2005.
The EFSA Journal 2006, 94:28–32.
32. European Food Safety Authority (EFSA): The community summary report
on trends and sources of zoonoses, zoonotic agents, antimicrobial
resistance and foodborne outbreaks in the European Union in 2006.
The EFSA Journal 2007, 130:24–30.
33. Simonsen J: Sero-epidemiology as a tool to estimate the incidence of
important and frequent infectious diseases. PhD thesis. University of
Copenhagen. Faculty of Health Sciences 2011, :63–67.
34. Kemmeren JM, Mangen MJ, van Duynhoven YT, Havelaar AH: Priority
setting of foodborne pathogens. Bilthoven: RIVM; 2006:55–58. report
330080001/2006.
doi:10.1186/1471-2458-12-523
Cite this article as: Falkenhorst et al.: Serological cross-sectional studies
on salmonella incidence in eight European countries: no correlation
with incidence of reported cases. BMC Public Health 2012 12:523.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
